CYP4F22: A Potent Drug Target for Statins and DILI (G126410)

Target Name: CYP4F22

NCBI ID: G126410

CYP4F22

CYP4F22: A Potent Drug Target for Statins and DILI

CYP4F22 (ARCI5) is a protein that is expressed in various tissues throughout the body, including the brain, heart, liver, and kidneys. It is a member of the CYP4 family, which is involved in the synthesis of a variety of compounds, including drugs, toxins, and waste products. ARCI5 is unique because it is a potent inhibitor of the enzyme CYP3A4, which is responsible for metabolizing a wide variety of drugs.

The CYP3A4 enzyme is an important drug target because it is involved in the metabolism of many drugs, including many statins, which are used to treat cholesterol and heart disease. By inhibiting CYP3A4, drugs that are metabolized by this enzyme are reduced in their levels in the body, which can reduce the risk of side effects and increase the effectiveness of the drug.

ARCI5 is also a potential biomarker for the diagnosis and monitoring of drug-induced liver injury (DILI). DILI is a serious complication that can occur as a result of taking certain drugs, including statins. It can cause inflammation and damage to the liver, which can lead to serious health consequences if left untreated.

The CYP4F22 protein is a potential drug target because of its ability to inhibit the activity of CYP3A4, which is involved in the metabolism of many drugs. By targeting this enzyme, drugs that are metabolized by CYP3A4 can be reduced in their levels in the body, which can reduce the risk of side effects and increase the effectiveness of the drug.

In addition to its potential as a drug target, ARCI5 is also a potential biomarker for the diagnosis and monitoring of drug-induced liver injury (DILI). DILI is a serious complication that can occur as a result of taking certain drugs, including statins. It can cause inflammation and damage to the liver, which can lead to serious health consequences if left untreated.

The CYP4F22 protein is a unique protein that is involved in the synthesis of a variety of compounds, including drugs, toxins, and waste products. It is also a potent inhibitor of the enzyme CYP3A4, which is responsible for metabolizing a wide variety of drugs. These properties make it an attractive target for drug developers who are looking for new and effective treatments for a variety of diseases.

In conclusion, CYP4F22 (ARCI5) is a protein that is expressed in various tissues throughout the body and is a member of the CYP4 family. It is unique because it is a potent inhibitor of the enzyme CYP3A4, which is involved in the metabolism of many drugs. In addition, ARCI5 is also a potential biomarker for the diagnosis and monitoring of drug-induced liver injury (DILI). These properties make it an attractive target for drug developers who are looking for new and effective treatments for a variety of diseases.

Protein Name: Cytochrome P450 Family 4 Subfamily F Member 22

Functions: A cytochrome P450 monooxygenase involved in epidermal ceramide biosynthesis. Hydroxylates the terminal carbon (omega-hydroxylation) of ultra-long-chain fatty acyls (C28-C36) prior to ceramide synthesis (PubMed:26056268). Contributes to the synthesis of three classes of omega-hydroxy-ultra-long chain fatty acylceramides having sphingosine, 6-hydroxysphingosine and phytosphingosine bases, all major lipid components that underlie the permeability barrier of the stratum corneum (PubMed:26056268). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase) (PubMed:26056268)

The "CYP4F22 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CYP4F22 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets